Results 241 to 244 of about 692,791 (244)

Pharmacogenetic and microRNA mechanisms of beta blocker use on bone. [PDF]

J Bone Miner Res
Lary CW, Atkinson EJ, Spillane J, Nayema Z, Roy TA, Peters R, Scott GT, Chen H, Nagarajan A, Brown A, Motyl KJ, Monroe DG, Khosla S.   +12 more
europepmc   +1 more source

Pre-admission beta-blocker therapy and outcomes in cardiogenic shock: Insights from the Altshock-2 Registry. [PDF]

ESC Heart Fail
Pagnesi M, Riccardi M, Sacco A, Tavecchia G, Viola G, Frea S, Briani M, Bertoldi LF, Bertaina M, Potena L, Valente S, Marini M, De Ferrari GM, D'Ettore N, Cardinale A, Camporotondo R, Rota M, Tavazzi G, Morici N, Pappalardo F, Metra M, Altshock‐2 investigators.   +21 more
europepmc   +1 more source

Utility of Cardiopulmonary Exercise Testing in Assessing Beta-Blocker Efficacy in LQTS: Moving Away From One-Size-Fits-All. [PDF]

J Cardiovasc Electrophysiol
El Assaad I, Heilbronner AK, Zahka K, Hammond B, Patel A, Aziz PF.   +5 more
europepmc   +1 more source

Beta blocker use and breast cancer survival by subtypes: A population-based cohort study. [PDF]

Breast
Scott OW, Tin Tin S, Botteri E.
europepmc   +1 more source